Table 3.
Cox regression for time to first occurrence of DAIDS Grade 3 or 4 ALT and/or AST abnormalities in TPV/r-based and comparator PI/r- (CPI/r-) based cART RESIST patients
| Parameter | HR1 (p-value) | 95% Confidence Interval |
|---|---|---|
| Treatment group: | 2.77 (<0.0001) | 1.71, 4.48 |
| TPV/r v CPI/r | ||
| HBV or HCV co-infection: | 2.00 (0.0057) | 1.22, 3.27 |
| yes vs. no | ||
| ALT/AST at baseline: | 2.05 (0.0709) | 0.94, 4.48 |
| Grade ≥2 vs. ≤Grade 1 | ||
| CD4+ cells at baseline: |
1.46 (0.0643) | 0.98, 2.18 |
| >200 vs. ≤200 cells/mm3 | ||
1 Hazard Ratio
Model further controlled for sex, race and concurrent use of T-20 (none were statistically significant).